ストックスクリーナーアプリを入手
9.27
0.87%
0.08
アフターアワーズ：
9.27
前日終値:
$9.19
開ける：
$9.19
24時間の取引高:
118.62K
Relative Volume:
0.79
時価総額：
$2.80B
収益：
$391.87M
当期純損益:
$-441.45M
株価収益率:
-5.0108
EPS:
-1.85
ネットキャッシュフロー:
$-301.21M
1週間 パフォーマンス:
-10.52%
1か月 パフォーマンス:
-16.49%
6か月 パフォーマンス:
-24.63%
1年 パフォーマンス:
-20.70%
1日の値動き範囲:
$9.19
$9.34
1週間の範囲:
$9.15
$10.25
52週間の値動き範囲:
$9.15
$14.76
Alvotech Stock (ALVO) Company Profile
ALVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
9.27 | 2.80B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
159.61 | 71.47B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.19 | 47.98B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.45 | 47.20B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.85 | 17.02B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
307.36 | 13.80B | 2.76B | 1.11B | 898.10M | 22.77 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | 開始されました | UBS | Buy |
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | アップグレード | Citigroup | Sell → Neutral |
| 2023-09-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-07 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-06 | ダウングレード | Citigroup | Buy → Sell |
| 2022-07-26 | 開始されました | Citigroup | Buy |
すべてを表示
Alvotech (ALVO) 最新ニュース
The Escalator: HHS, Spectrum Science, Alvotech and more - Medical Marketing and Media
Oaktree Capital Management LP Sells 606,322 Shares of Alvotech (NASDAQ:ALVO) - MarketBeat
Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs - insights.citeline.com
Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year - Center for Biosimilars®
Alvotech (NASDAQ:ALVO) Issues Earnings Results - MarketBeat
Alvotech (NASDAQ:ALVO) Stock Price Down 7.6%Time to Sell? - MarketBeat
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge By Investing.com - Investing.com Australia
Aurion names Arnaud Lacoste CEO - BioCentury
Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024 - insights.citeline.com
Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Alvotech Achieves Record Revenue Growth in 2024 - TipRanks
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge - Investing.com India
Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker - Bloomberg.com
Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer - MarketScreener
Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position - TipRanks
Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline - TipRanks
Iceland's Alvotech Appoints Chief Strategy Officer - MarketScreener
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - The Manila Times
Alvotech earnings missed by $0.04, revenue topped estimates - Investing.com Australia
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech earnings missed by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech : Press Release Full Year 2024 - MarketScreener
Alvotech Reports Record Results for 2024 and Provides Business Update - The Manila Times
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Alvotech And Advanz Make First Omalizumab Filing - Citeline News & Insights
Alvotech SA MHRA Accepts Marketing Application For AVT23 Biosimilar To Xolair - Marketscreener.com
Alvotech’s Biosimilar to Xolair Gains UK Regulatory Acceptance - TipRanks
Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair - MarketScreener
UK Medicines and Healthcare Products Regulatory - GlobeNewswire
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - The Manila Times
Earnings Scheduled For March 26, 2025 - Benzinga
UK Medicines and Healthcare Products Regulatory Agency - GlobeNewswire
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewswire Inc.
Royce & Associates LP Raises Stock Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech, Partners Say UK Regulator Accepted Market Application for Proposed Xolair Biosimilar - Marketscreener.com
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars - MSN
Alvotech (ALVO) Expected to Announce Earnings on Wednesday - MarketBeat
Short Interest in Alvotech (NASDAQ:ALVO) Expands By 21.7% - MarketBeat
Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003 - MSN
FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars - Drug Store News
Northland reiterates Alvotech stock with $28 target on acquisition By Investing.com - Investing.com Canada
Alvotech Acquires Xbrane's R&D Operations, Expanding Biosimilars Development Capabilities - Nasdaq
Northland reiterates Alvotech stock with $28 target on acquisition - Investing.com India
Icelandic Biotech Company Alvotech to Explore Listing in Stockholm - MarketWatch
Alvotech (ALVO) 財務データ
収益
当期純利益
現金流量
EPS
9.75%
大文字化:
|
ボリューム (24 時間):